A Multicenter Study for the Validation of ALS Biomarkers

The primary objective of this study is to identify factors that contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS). Development of disease biomarkers and diagnostic laboratory tests would facilitate earlier treatment intervention, help monitor treatment efficacy, and ultimately, lead to the identification of targets that could be used in therapy development.

The ALS Center of Oregon is one of the 35 ALS centers of the Northeast ALS (NEALS) Consortium in the US and Canada currently participating in this trial. We are actively recruiting study participants with ALS, other neuromuscular diseases as healthy people.


We have recently completed two drug trials: the Minocycline trial and the Combination Therapy Selection Trial with Minocycline-creatine or Celecoxib-creatine.  An article was published by Dr. Paul Gordon in August 2008 in the medical journal “Amyotrophic Lateral Sclerosis” based on the results of the Combination Therapy Selection Trial. Through neither of these trials yielded promising results, researchers still gained useful insight into ALS they will help investigators identify future ALS research. 

Please contact Diana Dimitrova at 503 494-7269 if you or someone you know is interested in participating in research at the ALS Center of Oregon.